TRIAL DATA
Perioperative Pembrolizumab Shows High Complete Response Rate in MSI-H/dMMR Localized Colorectal Cancer — Journal of Clinical Oncology
Journal of Clinical Oncology. MSI-H/dMMR tumors have defects in DNA repair machinery that make them highly responsive to immunotherapy.
What this means
If you have MSI-H or dMMR colorectal cancer that hasn't spread beyond the colon, immunotherapy before surgery may become a new treatment option. Ask your care team whether your tumor has been tested for MSI-H/dMMR status and if perioperative immunotherapy trials are available.